RecruitingNot ApplicableNCT07053982

Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions

18F]-FES PET in the Detection and Characterization of Endometriosis Lesions

Sponsor

University Hospital, Toulouse

Enrollment

20 participants

Start Date

Mar 23, 2026

Study Type

INTERVENTIONAL

Conditions

Endometriosis

Summary

Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. \[18F\]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of \[18F\]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria9

Cases:
\- Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis;
Controls:
Patient with a VAS \< 4 treated surgically for endometriosis in the context of infertility;
Age \> 18 years;
Patient who provided informed consent;
Patients who underwent a preoperative MRI and were not contraindicated for \[18F\]-FES PET/CT;
Patient who underwent surgery mid-cycle;
Affiliation to a social security scheme

Exclusion Criteria7

Patient treated for endometriosis without surgery;
Pregnant patient
Patient taking hormone therapy
Menopausal patient
Hypersensitivity to the active substance (Fluoroestradiol (18F)) or to any of the excipients
Patient under legal protection
Claustrophobic patient

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREPreoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery

This study includes preoperative \[18F\]-FES PET/CT imaging to assess estrogen receptor expression in endometriosis patients undergoing laparoscopic or robot-assisted surgery. Pain levels will be evaluated using VAS, BPI, HADS, and SF-36 scales. Immunohistochemistry and quantitative mRNA expression analysis (ESR1, ESR2, GPER) will be performed on excised lesions using Tissue Microarray. This approach aims to correlate PET/CT imaging findings with histological and molecular data, distinguishing it from standard surgical interventions.